Elsevier

Annals of Oncology

Volume 33, Issue 4, April 2022, Pages 451-453
Annals of Oncology

ESMO Virtual Plenary Abstract
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

https://doi.org/10.1016/j.annonc.2022.02.224Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

© 2022 European Society for Medical Oncology. Published by Elsevier Ltd.